Loading company…
ProteoBridge develops protein microarrays and test kits for autoantibody research and validation.
Founded in 2018, ProteoBridge is based in Tokyo, Japan, and develops protein microarrays and diagnostic test kits for autoantibody detection. Its HuPEX™ array supports proteome-wide searches. In June 2022, the company raised JPY 180 million in Series A funding from Mirai Creation Capital.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in